Drug deposition in coronary arteries with overlapping drug-eluting stents by Olgac, Ufuk et al.
Drug deposition in coronary arteries with overlapping drug-
eluting stents
Farhad Rikhtegara, Elazer R. Edelmana,b, Ufuk Olgacc, Dimos Poulikakosd, and Vartan 
Kurtcuogluc,e
aInstitute for Medical Engineering and Science, Massachusetts Institute of Technology, 
Cambridge, MA, USA bCardiovascular Division, Brigham and Women’s Hospital, Harvard Medical 
School, Boston, MA, USA cThe Interface Group, Institute of Physiology, University of Zurich, 
Zurich, Switzerland dLaboratory of Thermodynamics in Emerging Technologies, Department of 
Mechanical and Process Engineering, ETH Zurich, Zurich, Switzerland eZurich Center for 
Integrative Human Physiology and National Center of Competence ‘Kidney.CH’, University of 
Zurich, Zurich, Switzerland
Abstract
Drug-eluting stents are accepted as mainstream endovascular therapy, yet concerns for their safety 
may be under-appreciated. While failure from restenosis has dropped to below 5%, the risk of 
stent thrombosis and associated mortality remain relatively high. Further optimization of drug 
release is required to minimize thrombosis risk while maintaining therapeutic dose.
The complex three-dimensional geometry of deployed stents together with the combination of 
diffusive and advective drug transport render an intuitive understanding of the situation 
exceedingly difficult. In situations such as this, computational modeling has proven essential, 
helping define the limits of efficacy, determine the mode and mechanism of drug release, and 
identify alternatives to avoid toxicity.
A particularly challenging conformation is encountered in coronary arteries with overlapping 
stents. To study hemodynamics and drug deposition in such vessels we combined high-resolution, 
multi-scale ex vivo computed tomography with a flow and mass transfer computational model. 
This approach ensures high geometric fidelity and precise, simultaneous calculation of blood flow 
velocity, shear stress and drug distribution.
Our calculations show that drug uptake by the arterial tissue is dependent both on the patterns of 
flow disruption near the wall, as well as on the relative positioning of drug-eluting struts. 
Overlapping stent struts lead to localized peaks of drug concentration that may increase the risk of 
thrombosis. Such peaks could be avoided by anisotropic stent structure or asymmetric drug release 
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designed to yield homogeneous drug distribution along the coronary artery and, at the least, 
suggest that these issues need to remain in the forefront of consideration in clinical practice.
Graphical abstract
1 Introduction
Drug eluting stents (DES) suppress neointimal hyperplasia and reduce angiographic 
restenosis seen in their bare metal stent (BMS) counterparts, but are not free of these disease 
processes [1–4]. DES angiographic and clinical restenosis increase with lesion complexity, 
and especially when multiple and overlapping stents are implanted [5]. The use of multiple 
stents and the intervention on long lesions virtually necessitate stent overlap, and is indeed 
present in more than one in three patients undergoing percutaneous coronary intervention 
(PCI) [6, 7]. Overlap is the one major category of interventions where new designs have not 
had as great an impact as seen in other use domains [8–10]. While some investigators have 
reported the safety and effectiveness of overlapping DES being comparable to those 
experienced with single long or multiple short stents [11–13], more recent publications have 
raised concerns about negative outcomes [14–18]. Regardless of stent type, stent overlap has 
been associated with increased instent restenosis (ISR) and lumen loss due to delayed 
healing and increased inflammation [6, 19, 20].
Stent overlap interferes with the two major goals of placement optimization – reduction in 
interference with luminal flow and minimization of mural injury. It is simply impossible to 
have complete apposition without exacerbating vascular injury, and/or minimal vascular 
injury without significant alteration in arterial hemodynamics. Stacking of stents creates 
regions of stagnation, separation and recirculation, the extent of which depends on stent 
geometry, asymmetric change of stent cell structure due to implantation and relative 
geometric configuration of overlapping struts [21–23]. These effects may result in wide 
variations in mural drug concentration with areas of depletion and excessive concentration 
[22, 24] exactly where precise control of drug delivery and retention is needed most – in the 
areas of injury. Overlapping struts or multiple struts in close proximity may increase the risk 
of local cytotoxicity, persistent inflammation [25], amplification of thrombogenic effects as 
a hypersensitivity reaction of the local vasculature to a specific polymer and/or drug [25, 
26], stent thrombosis and in-stent restenosis [6, 21, 27] as a consequence of increased 
arterial injury, poor endothelization and delayed healing [18, 25, 28].
The issues are thus profoundly complex, as we must now account for a balanced integration 
of drug delivery, vascular injury and flow disruption – considerations that defy intuition and 
are too costly to embrace in all its permutations in any experimental setting. This situation 
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calls for a computational modeling approach with which the number of parameters as well 
as their scope can be reduced to experimentally tractable sizes.
Previous computational models have employed isolated struts devoid of complete designs, 
theoretical constructs and primarily two-dimensional systems [21, 24, 29, 30]. While they 
make a point, they fail to integrate the complete interactions between adjacent struts and the 
limitations imposed by real systems. More intricate designs of strut cells provide stents with 
more flexibility and ease of deployment and enhance the apposition even in case of stent 
overlap. However, in the presence of complex target lesions, malposition of struts is more 
pronounced especially in case of overlap, which results in greater disruption of near-wall 
flow [31]. Thus, simple consideration of two-dimensional primary systems, e.g. [24, 29, 30], 
will not allow for accurate modeling of the three-dimensional patterns of violated flow in 
arteries with overlapping stents.
Here we present a combined experimental and computational framework for the 
determination of hemodynamics and drug elution in stented arteries. Following a 
methodology we have developed and previously described in detail [32], we resolve the 
precise three dimensional geometry of stented arteries from microscale computed 
tomography data, ensuring high geometric fidelity both at the whole stent as well as at the 
individual strut scale. In conjunction with computational modeling, this allows prediction of 
drug distribution and deposition in anatomically accurate arteries under physiologic and 
pathophysiologic flow conditions. We show that taking into account the relative positioning 
of overlapping struts as well as arterial deformation warrants more realistic estimation of 
drug uptake by the tissue and highlights several hemodynamic and consequent 
pharmacodynamics outcomes which are the predecessors of reported clinical events.
2 Methods
2.1 Ex vivo preparation of model: Stent implantation, vascular corrosion casting
The left coronary artery of an ex vivo porcine heart was cannulated, and an interventional 
cardiologist implanted two absorbable magnesium alloy scaffolds of 10 mm length and 3 
mm diameter (Biotronik AG, Bülach, Switzerland) under angiographic guidance. Care was 
taken to ensure reproducible 20% overlap of the stents. Note that in the computational model 
the scaffolds are treated as permanent drug eluting stents (see Section 2.3).
A radio-opaque casting material was prepared by mixing the low-shrinkage epoxy-based 
Biodur E20 resin (Biodur Products GmbH, Heidelberg, Germany) and iodine-saturated 
methyl ethyl ketone solvent. Using a pneumatic apparatus, the casting material was injected 
under physiological pressure of 90 mmHg (120 mbar) to accurately capture the arterial tree. 
The heart was maintained at room temperature for 36 hours, and then macerated for 12h at 
55 °C in a 7.5% w/v solution of potassium hydroxide. The final product was rinsed with 
water several times to remove remaining adherent tissue.
A more detailed description of the ex vivo preparation can be found in [31, 32].
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2.2 Scanning and Image processing: µCT imaging of casts, segmentation and registration
The overall geometry of the arterial tree was captured using micro-computed tomography 
(µCT 80, Scanco Medical AG, Brüttisellen, Switzerland) with an isotropic voxel size of 74 
µm (energy 70kVp, integration time 300 ms, tube current 114 µA, and two times frame 
averaging). The stented arterial segment was dissected and re-scanned (µCT 40, Scanco) 
with an isotropic voxel size of 6 µm (energy 70kVp, integration time 300 ms, tube current 
114 µA, and two times frame averaging) to obtain higher resolution images. This strategy 
enabled us to resolve the individual stent struts as well as the overall arterial geometry while 
keeping scan time and associated costs at bay.
To partly suppress noise in the raw µCT volumes, a constrained 3D Gauss filter was applied 
(σ = 1.2, s = 1.0). Using a semi-automatic, intensity-based approach in Avizo 6.2 
(Visualization Sciences Group SAS, Merignac, France), both µCT datasets of low and high 
resolution were independently segmented to obtain the lumen geometry. The resulting 3D 
geometry was exported to Geomagic Studio 12 (Geomagic, Inc., Morrisville, NC, USA), 
wherein the high resolution geometry of the stented segment and the lower resolution 
remainder of the arterial tree were registered and merged. Assuming 500 microns as a 
nominal value of a coronary artery wall thickness (smaller than human vascular thickness 
[33]), the vascular wall was generated by numerical expansion of the segmented lumen 
boundary. The obtained geometry was exported in STL format for subsequent computational 
grid generation.
2.3 Computational set-up and governing equations
ANSYS ICEM CFD (ANSYS, Inc., Canonsburg, PA, USA) was used to generate a 
computational grid of approximately 85 million tetrahedral elements in the merged 
geometry. A sequential CFD and mass transfer model was applied to conduct steady-state 
blood flow and mass transfer analysis for determining the blood velocity inside the artery 
and drug distribution in the lumen and the arterial wall. The following mass and momentum 
conservation equations were solved inside the lumen:
(5.1)
(5.2)
where , ρ, P and μ are the blood flow velocity vector inside the lumen, density, pressure 
and dynamic viscosity, respectively. Blood was modeled as a non-Newtonian incompressible 
fluid with constant density of 1050 kg/m3 and shear-dependent dynamic viscosity according 
to the Carreau model [34]. Blood was assumed to enter the coronary artery at a flow rate of 
0.95 mL/s at the ostium [35]. No slip boundary conditions were set at the stent wall, while 
on the vessel wall the transmural velocity of plasma was applied in the normal direction 
according to the pre-calculated luminal pressure distribution and resistance of the tissue 
excluding endothelial resistance as explained in [36, 37]. Murray’s law was applied at the 
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outlets, to where the outlet with the largest diameter was set to 70 mmHg relative pressure, 
and the remaining outlets were assigned outflow rates according to their cross-sectional area 
[32, 38]. Drug transport inside the lumen was determined by the advection-diffusion 
equation
(5.3)
where Cl is the drug concentration within the fluid domain and Dl denotes the diffusivity of 
the drug. Paclitaxel served as the model drug, with its diffusivity of 3.89 × 10−11 m2/s in 
blood [39]. Zero drug concentration was assigned at the ostium. Open boundary conditions 
as well as flux conservation were assumed at the outlets and the mural interface, 
respectively. Constant unit concentration was set on the stent struts.
Similarly, the continuity and momentum conservation equations were solved for inside the 
arterial wall, which was modeled as a porous medium:
(5.4)
(5.5)
where  is infiltrated fluid velocity inside the arterial wall and momentum is updated 
according to Darcy’s law with K, the permeability of wall, having the value of 1.43 × 10−14 
cm2 [39, 40]. No endothelial resistance was considered due to the assumption of complete 
endothelial denudation as a result of stenting [23]. Same normal transmural velocity 
(explained above) was applied as boundary condition at the luminal side of the arterial wall. 
Perivascular pressure was set to 17.5 mmHg [36, 37].
As in the lumen, drug transport inside the arterial wall is also governed by the advection-
diffusion equation,
(5.6)
where Cw is the concentration of the drug inside the artery wall and Dw the corresponding 
drug diffusivity with the value of 3.65 × 10−12 m2/s [39]. Open boundary conditions were 
prescribed at the perivascular border and the longitudinal ends of the considered arterial wall 
segment.
Calculations were carried out with the convergence criterion set to residual reduction to 10−8 
of the initial value. 64 AMD Opteron 6174 processor cores were used. Grid independence 
Rikhtegar et al. Page 5
J Control Release. Author manuscript; available in PMC 2017 September 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
studies were performed to ensure independence of the results from the used computational 
mesh.
3 Results
In the following we present the calculated concentration of paclitaxel in the lumen and 
vascular wall of an ex vivo stented porcine left coronary artery. We show the effect of stent 
overlap in terms of flow disruption and thereby caused changes in drug distribution. To 
assess the effect of overlapping DES on vascular drug deposition we compare results of 
cases where only the proximal or distal stent (henceforth referred to as Proximal DES or 
Distal DES, respectively), or both elute drug (Overlap DES) (Figure 1).
Flow effects on mural drug deposition are increased in Overlap DES (Figure 2), the drug 
concentration is high in the vicinity of stent struts and at certain locations around the area of 
overlap. The recirculation zones and flow separation close to the struts induce an 
asymmetric drug deposition contour in the longitudinal flow direction in agreement with 
previous reports [39, 41]. Stent overlap causes higher local drug peak concentrations which 
are expected to arise not only due to higher local drug load but also more direct contact of 
the drug eluting struts and tissue and, more important for us, disrupted blood flow.
The relative strut configuration plays an important role in the drug deposition profile deep 
into the vessel wall (Figure 3) with higher concentration of drug at the site of overlap and in 
vicinity of inter-strut connectors. A large drug concentration gradient within the arterial wall 
is observed with concentrations peaking in the immediate vicinity of stent struts, and 
reducing with increasing distance from them. Furthermore, it appears that the luminal flow 
alleviates the extreme spatial heterogeneity of drug distribution that would be expected in 
the case of solely diffusive transport.
The flow-disrupting effect of overlapping struts extends drug well beyond the site of release 
(Figure 4A, B and C) – an effect more pronounced for cases with single drug-eluting stent. 
Drug concentration is notably high in locations with large flow recirculation zone caused by 
congruent overlapping stent struts. The area proximal to the overlap region is only 
marginally affected by flow disruption (Figure 4D), and in this region Proximal and Overlap 
DES cases differ in drug deposition only in the immediate vicinity of stent struts where 
small recirculation zones are generated. However, inside the overlap region (segments 2 and 
3 in Figure 4D) large recirculation zones increase drug residence time and reduce flow-
induced washout. Proximal to segment 3, blood can flow in between congruent struts since 
there is a comparably large distance between the inner- and outermost struts, increasing 
blood velocity, decreasing recirculation zone size and with it drug pooling. As a result, more 
drug is advected to the mural surface and into the arterial wall. Immediately distal to the 
overlap region (segment 4), the Overlap DES and Distal DES cases feature comparable drug 
concentration maps on the mural surface, with slightly higher concentration in the Overlap 
DES case due to drug elution from both stents. Interestingly, this leads to slightly higher 
concentration inside the tissue in the Distal DES case compared to when both stents are 
drug-eluting. Ultimately, the drug concentration just beneath congruent overlapping struts 
shows similar profile peaking right above the protruded strut for both Overlap and Distal 
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DES cases. Moving farther in either proximal or distal direction, the flow-mediated effect of 
drug pooling and advective drug transport increases the drug concentration inside the tissue 
in the Overlap DES case.
To quantify the effect of overlap when the overlapping struts are both apposed to the artery, 
we compared the drug deposition on the mural interface and one half stent width into the 
tissue (Figure 5). In the Overlap DES case (Figure 5C), the proximity of two drug-eluting 
struts not only increases the available drug load, but also generates a recirculation zone 
between the overlapping struts, which increases drug pooling and transfer to the tissue. The 
latter also increases drug concentration in cases where the proximal or distal strut does not 
elute drug (Distal/Proximal DES cases). Drug delivery is more effective when the drug-
eluting stent is implanted abluminally (Figure 5A and B). On the mural wall, the drug 
concentration away from the stent struts is more than double the value found in the 
congruent case (Figure 4D and 6D). Moreover, the mural drug concentration is considerably 
higher when the drug-eluting stent is located distally. This shows that the drug concentration 
is mainly determined by flow-mediated effects. Overlapping drug-eluting struts in close 
proximity to each other act as one large obstacle, generating a larger recirculation zone 
proximal to the struts and thereby causing a slight shift in concentration pattern beneath the 
proximal strut (Figure 5D2). An interesting observation is also that while the Proximal DES 
case shows much lower mural concentration, the peak concentration in that case is higher 
compared to Distal DES as a result of flow-mediated drug delivery caused by the larger drug 
pool proximal to the drug-eluting stent. While, from a qualitative point of view, these results 
are in line with observations of previous two-dimensional simulations [24], the spatial 
variations seen here can only be obtained with three-dimensional models.
To further quantify the drug deposition map, Area-Weighted Average drug Concentration 
(AWAC) is calculated for the proximal, overlapping and distal segments of the stented 
region, plus for a single distal non-stented segment for the three cases of Proximal, Distal 
and Overlap DES (left panel of Figure 6). The AWAC is always higher when both stents 
elute drug (Overlap DES). This dominance is minimized in the proximal segment, where the 
flow mediated difference and effect of overlap on drug load is negligible. In the overlap 
segment, the AWAC for Overlap DES is 420% and 34% higher than f0r Proximal and Distal 
DES, respectively. This shows that the flow-mediated effects increase the mural drug 
concentration considerably, but are more pronounced when the drug-eluting struts are 
abluminally implanted. It further shows that the second drug-eluting stent does not directly 
double the mural drug concentration, although the overall drug load is doubled. Finally, the 
highest mural concentration is found in the overlapping segment, where the availability of 
drug and flow disruption is maximized. For a non-stented region quite distal to the overlap 
segment, the AWAC is still higher for the case of Overlap DES, showing how the drug 
washed out by the flow alters drug deposition quite a distance from the strut overlap.
The total uptake of drug in the arterial wall, here expressed as Volume-Weighted Average 
drug Concentration (VWAC), is highest in the overlap region (Figure 6, right panel). The 
higher value of VWAC where the struts are abluminally apposed shows how crucial the 
direct contact of drug-eluting stent is to the accumulation of drug inside the arterial wall. 
The less pronounced difference between Overlap and Distal DES cases at the site of overlap 
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highlights the dominance of direct contact over the flow-mediated drug delivery mechanism. 
Interestingly, drug uptake by the tissue is higher in the distal segment in the Distal DES 
compared to Overlap DES case. Observing tissue drug uptake in a location without stent 
contact (named ‘Distal not stented’), we note a significant decrease in VAWC for 
comparably lower reduction of AWAC. This again highlights the importance of the drug 
delivery via direct contact compared to drug transfer by near-wall flow.
4 Discussions
Overlapping stents have been compared to thick-strut devices, yet our results show that the 
issues with overlap extend well beyond the creation of recirculation zones. Our use of three-
dimensional modeling allows for control over geometry not possible in animal models, and 
enables the capture of features not observable in 2D models [21, 24, 29, 30]. Arterial drug 
uptake is dependent on the patterns of flow disruption near the wall and the relative 
positioning of drug eluting struts. Overlapping struts localize drug concentration peaks. 
Three-dimensional modeling helps explain how a stent apposed to the artery wall can 
influence drug delivery from a second stent lying on top. The embedded struts of the 
apposed stent deliver substantial amount of drug to the wall due to direct contact. Net uptake 
by the tissue of drug released into the blood stream from the protruded struts of the second, 
overlapping stent depends on the drug concentration gradient across the luminal border. And 
this concentration gradient is directly related to the amount of drug delivered to the artery 
wall by the apposed stent.
The high spatial variation of drug deposition after DES implantation is caused by 
heterogeneous hemodynamics resulting from the interaction of local three-dimensional flow 
with anisotropic stent design, which ultimately leads to an asymmetric drug concentration 
map (Figure 2)) [23, 24, 29, 30]. Interstrut spacing can now be visualized in 3D as an 
extension of overlap where struts adjacent to each other in the longitudinal domain can be 
understood to modulate the concertation gradient drive in a complex manner. Congruently 
overlapped struts, like individual thick struts, contribute to greater surface drug 
concentration drive into the tissue. This occurs in a manner where flow can play an even 
greater role as recirculation zones are expanded. However, the increase in drug deposition is 
lower than predicted by two-dimensional modeling [24], highlighting the limitation of the 
latter, simpler approach, and at the same time emphasizing the need for an accurate, three-
dimensional account of hemodynamics and drug transport. When incongruent or staggered, 
the concentration gradients from individual struts can defeat each other and may not 
establish large recirculation zones (Figure 4 and Figure 5). Thus, we can now appreciate 
why drug deposition can be highly variable in areas distal or proximal to the stented segment 
– variable but not random: as our results indicate, the variability arises from the relative 
configuration of stent struts and inter-strut connectors due to the effect of convectively 
delivered drug. Hence, the overall drug uptake by the arterial tissue is not only determined 
by direct contact of drug eluting struts with the arterial wall, but also a result of flow-
mediated transport.
In addition to increasing the direct contact between the arterial tissue and the drug-eluting 
struts, overlapping stents amplify the drug load in the vicinity due to alteration of blood 
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flow. Strut embedment increases drug concentration in the wall and decreases the amount of 
drug advected to distal regions. On the other hand, protrusion of the stent struts disrupts the 
flow field and induces flow separation and recirculation zones that modulate the drug 
deposition in the vascular wall and on the mural surface. This phenomenon also alters drug 
delivery to regions between struts and minimizes the gap between local minimum and 
maximum drug concentration values. The resultant effect of increased drug deposition due to 
stent overlap greatly depends on the relative strut configuration, and is more pronounced, 
both on the mural surface and inside the tissue, when the struts of overlapping stents are 
positioned very close to each other. Indeed, since blood flow extends drug deposition beyond 
the area of stent-tissue contact, the complex interaction of stent struts with the arterial wall 
and the flow field needs to be taken into account. For instance in some cases, the peak 
concentration of delivered drug will not be just symmetrical beneath the implanted strut, as 
one might expect by intuition, but shifted towards the direction dictated by hemodynamic 
forces. Therefore, it may be prudent to put more emphasis on such flow effects in the stent 
design process and consider them during stent deployment. It is possible that some negative 
outcomes associated with DES may be linked to unexpected patterns of flow-induced drug 
deposition.
In the case of stent overlap, malapposition and the effect of flow disruption will modulate 
the amount of drug uptake by the arterial tissue. While the amount of drug available at the 
luminal arterial surface increases with overlapping stents, it is not linearly dependent on the 
amount of drug on the stent struts, but co-determined by the local flow field (Figure 6). And 
again, there is large spatial variation in the flow field, which cannot be captured with a two-
dimensional modeling approach.
The increase of drug deposited on the mural surface in case of overlap may lead to delayed 
vascular healing, which is a well-known issue in the treatment with DES [42]. This 
phenomenon, along with increased drug uptake distally and in inter-strut regions, highlights 
the complexity of the interaction between the flow-mediated distribution of released drug 
and drug uptake further downstream. If, in addition, one considers temporal changes caused 
by intimal hyperplasia, the complexity of the situation becomes even more pronounced. The 
important case of overlap, increasing the peak concentrations locally, may also complicate 
the total drug uptake due to the important role of local flow and inter-strut positioning. The 
overlap of stent struts and malapposition lead to considerable disruption of flow, extending 
drug delivery beyond the region of overlap. These near-wall flow-dependent features, 
although increasing the drug deposition on the mural wall as well as arterial drug uptake, 
will be more effective when the drug eluting struts are apposed to the arterial wall. Thus, in 
cases where the drug-eluting stent is not abluminally implanted, the overlap, and 
consequently flow disruption, will pool the drug in the vicinity of the mural surface and 
amass the drug on the lumen-tissue interface, but will not noticeably add to the volumetric 
concentration of drug inside the arterial wall, as the diffusion-governed drug transport to the 
tissue is gradient dependent.
Considering the area-weighted average drug deposition (Figure 6), we can conclude that 
flow-mediated transport induced by the positioning of stent struts in overlap segments 
increases the drug concentration on the mural surface and its deposition inside the arterial 
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wall at the overlap segment. Highest drug delivery is achieved when both of overlapping 
stents elute drug, and this is more pronounced at the site of overlap. The overlap of stent 
struts, whether they are drug-eluting or not, alters the drug deposition map more 
significantly at areas distal to the site of overlap than proximal. While strut overlap and 
flow-induced drug delivery affects predominantly drug deposition on the mural surface, drug 
uptake by arterial tissue is governed more by the direct contact of the stent struts. Although 
it is clear that the drug uptake by the tissue is indeed affected by the flow field, this effect is 
less important than the relative positioning and ab/adluminal installation of drug-eluting 
stents. Substantial drop of drug uptake by the arterial tissue at regions distal to the stented 
segment, despite comparably less-significant drop of luminal wall drug concentration 
(Figure 6), shows how crucial the role of stent direct contact is in arterial drug delivery. The 
non-zero drug uptake in these regions is, conversely, further proof of the direct impact of 
flow-induced heterogeneous drug delivery in areas well beyond the immediate reach of the 
stent struts.
Another factor of high clinical importance is the vascular injury induced by stent 
implantation. While increasing stent embedment would lead directly to augmented drug 
uptake, it would also lead to more vascular injury. In the complex scenario of stent overlap, 
the outer (first) stent is pushed further into the arterial wall, thereby causing more vascular 
injury, while the inner (second) stent causes more flow disturbance. Consequently, there will 
be localized peaks of drug concentration due to the outer stent’s large area of contact with 
the tissue, while its contribution to advective drug transport will be decreased due to smaller 
area of contact with blood. In contrast, the inner stent will contribute more to drug transport 
by blood flow, also generating recirculation zones that pool the drug locally and lead to a 
non-uniform drug distribution map. This underlines the significance of the interventionist’s 
decision between one long or multiple overlapping stents, and suggests that further 
considerations are needed for stent design and clinical follow up in cases with multiple 
stents.
4.1 Study limitations
While our study has demonstrated very clearly that three-dimensional rather than two-
dimensional modeling is required to capture spatial variations of drug distribution, it is also 
evident that our framework does not account for all relevant physiologic and 
pathophysiologic mechanisms. An essential complement to this framework would be the 
consideration of biological variability and vascular responses [43]. This would include 
multi-scale modeling of drug pharmacokinetics and metabolism [44], as well as tissue 
partitioning and drug binding [45] in a heterogeneous tissue structure with more realistic 
diseased vessel topography. In those cases, the time-dependence of drug release [46] and the 
process of drug binding to tissue proteins will more accurately determine the ultimate drug 
uptake [47, 48]. Assuming a more dynamic environment of biological host species, vascular 
response both to the intravascular implant and depleted drug in terms of intimal hyperplasia 
and thrombosis should also be included in future numerical models to better assess the 
efficacy of new generations of drug-eluting implants [49] in more sophisticated clinical 
routines such as overlap [50, 51]. Developing such an intricate model entails further in vivo 
studies to acquire empirical factors of the biological response of the artery to develop a 
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multi-scale, multi-modal tool. Nevertheless, simplified computational models, similar to the 
present approach, are still invaluable tools to reduce the number of contributing parameters 
and limit the search space for each playing factor to produce a viable experimental set-up 
and bring about an expedient platform to assess efficacy of endovascular implants and study 
their fundamental complexities.
5 Conclusions
Combining two invaluable assets of our tool to first capture the geometry of individual struts 
as well as deformation of vasculature as a result of stenting and then computing point-wise 
maps of velocity, shear stress and drug concentration along the arterial tree, we were able to 
investigate complex geometrical configurations and diverse stenting scenarios. Arterial drug 
uptake and concentration patterns are highly dependent on both the local near-wall flow and 
the stent strut location and relative positioning. Realistic estimation of pharmacodynamics 
compels taking into account the three-dimensional characteristics of blood flow to predict 
the predecessors of reported clinical outcomes. Our 3D realistic computational model 
highlights the paramount role of both flow-mediated effects as well as geometrical 
positioning and design of drug eluting stents in the prediction of the drug delivery to the 
stented artery, which is more asymmetric and counter-intuitive in case of stent overlap. 
Apposition of drug-eluting struts and their geometrical characteristics dominated the drug 
distribution map, wherein relative positioning of struts from multiple stents and implantation 
procedure modulate the hemodynamics and consequently drug distribution.
We intend our framework to serve as a test bed for the development of new DES designs that 
will minimize adverse clinical events currently caused by suboptimal drug distribution. To 
this end, expansion of the computational model to include the more complex issues that 
surround use of these devices, e.g. time-dependent kinematics of drug release and retention 
of drug inside arterial tissue, is needed. Further aspects that warrant attention are the 
vasculature’s response to the endovascular implant, heterogeneity of drug transport in 
different healthy and diseased vascular tissue layers, removal of drug by metabolism and 
correlation with clinical events from trials.
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Figure 1. 
The overall geometry of stented porcine left coronary artery. The inset shows the stented 
region and overlap of the proximal, adluminally implanted, with the distal stent. The 
protrusion of the stent struts inside the vascular wall is evident.
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Figure 2. 
Mural drug deposition in an artery. Insets show magnified views of drug concentration 
pattern in different locations in the vicinity of stent overlap. Values are given relative to the 
drug concentration on the stent surface. Higher drug concentrations are evident in areas 
where the stent struts overlap. Asymmetric pattern of drug deposition and also signs of 
convectively-delivered drug are observed
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Figure 3. 
Concentration of deposited drug (shown in logarithmic scale) on the mural interface and in 
the arterial wall. Values are given relative to the drug concentration on the stent surface. 
Inset shows a high magnification view of the drug concentration pattern in the stented 
segment. High drug deposition is noticed in the overlap region, especially where struts are in 
close proximity, and distal to inter-strut connectors.
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Figure 4. 
Drug concentration map in a section plane through two congruent struts in cases of drug 
elution by (A) the proximal (B) the distal and (C) both stents. Values are given relative to the 
drug concentration on the stent surface. W and L stand for the wall and lumen region, 
respectively. Drug pooling as a result of flow recirculation is evident at the site of overlap. 
(D) Plots of drug concentration along the lines (1) to (5) as defined in the section plane 
below panel (C). Lines (1) to (4) are located on the mural surface, whereas line (5) is 
midway inside the arterial wall right beneath two congruent struts.
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Figure 5. 
Drug concentration map in a plane of two abluminally apposed struts in different cases 
where (A) proximal (B) distal and (C) both stents are eluting drug. Values are given relative 
to the drug concentration on the stent surface. W and L stand for the wall and lumen region, 
respectively. Arterial drug uptake is considerably higher when both stents elute drug. (D) 
Plots of drug concentration on the mural surface and bellow two apposed overlapping struts, 
as defined in the inset. Line 1 and 2 are located on mural surface and inside arterial wall 
(half-width of strut width bellow) of apposed overlapping struts, respectively.
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Figure 6. 
Quantification of the drug concentration on the mural surface and inside the wall of different 
segments of stented artery as defined in the schematic at the top. The values for the mural 
surface are given as the area weighted average of drug concentration (AWAC, left chart). For 
the arterial wall they are given as volume-weighted average of drug concentration (VWAC, 
right chart) within the arterial tissue. Values are given relative to the drug concentration on 
the stent surface. AWAC and VWAC are higher in the overlap segment than in the proximal 
and distal regions when both stents elute drug. This is due to higher load of drug available 
and flow-mediated drug deposition.
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